2026-05-09T19:13:14Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/ijcem.000026 2017-11-01 PTZ.IJCEM:VOL3

Metabolic Effects of D-Chiro-Inositol and Myo-Inositol in Polycystic Ovary Syndrome Rim Hanna Tarek WehbeElizabeth Abou Jaoude<p>Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age.&nbsp; The&nbsp; pathogenesis&nbsp; has&nbsp; not&nbsp; been&nbsp; fully&nbsp; deciphered.&nbsp; PCOS&nbsp; is&nbsp; associated&nbsp; with&nbsp; insulin&nbsp; resistance&nbsp; (IR), menstrual irregularities, cardiovascular disease, obesity, hirsutism, infertility, and endometrial cancer. The use&nbsp; of&nbsp; D-chiro-inositol&nbsp; (DCI)&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; IR&nbsp; in&nbsp; PCOS&nbsp; has&nbsp; been&nbsp; controversial&nbsp; with&nbsp; contradictory data being published. Our objective is to evaluate the effect of DCI combined with myo-inositol (MI), and metformin on the metabolic outcomes of PCOS in a Lebanese women cohort. </p><p>This is a prospective study of 150 Lebanese women diagnosed with PCOS and treated with Ovacure® (DCI+MI+folic&nbsp; acid),&nbsp; or&nbsp; a&nbsp; combination&nbsp; of&nbsp; Ovacure®&nbsp; and&nbsp; metformin.&nbsp; Patients&nbsp; aged&nbsp; 13&nbsp; to&nbsp; 55&nbsp; years&nbsp; were randomly&nbsp; selected&nbsp; from&nbsp; different&nbsp; clinics&nbsp; in&nbsp; Beirut&nbsp; and&nbsp; Mount&nbsp; Lebanon.&nbsp; A&nbsp; questionnaire&nbsp; covering&nbsp; the personal&nbsp; and&nbsp; health&nbsp; status,&nbsp; physical&nbsp; activity,&nbsp; medications&nbsp; and&nbsp; anthropometrics&nbsp; was&nbsp; completed&nbsp; before enrolment. </p><p>The prevalence of obesity in our population was 35.3%. Although IR was more prevalent among obese women&nbsp; with&nbsp; PCOS,&nbsp; non-obese&nbsp; subjects&nbsp; were&nbsp; also&nbsp; found&nbsp; to&nbsp; have&nbsp; a&nbsp; significant&nbsp; incidence&nbsp; of&nbsp; IR.&nbsp; After&nbsp; a&nbsp; 6 months course of treatment with Ovacure®, a significant decrease in fasting glucose, HOMA-IR, Glycated Hemoglobin&nbsp; (HbA1c),&nbsp; Low&nbsp; Density&nbsp; Lipoprotein&nbsp; (LDL),&nbsp; Triglycerides&nbsp; (TG),&nbsp; weight&nbsp; and&nbsp; Body&nbsp; mass&nbsp; index (BMI)&nbsp; levels&nbsp; were&nbsp; noted.&nbsp; Furthermore,&nbsp; adding&nbsp; metformin&nbsp; to&nbsp; Ovacure®,&nbsp; lowered&nbsp; weight&nbsp; and&nbsp; BMI&nbsp; further but not IR.</p><p>In this study, we show that the combination of MI and DCI may improve the metabolic profile in PCOS.The addition of metformin may help control overweight further but not IR.</p> International Journal of Clinical Endocrinology and Metabolism - Peertechz Publications 2017-11-01 Research Article https://doi.org/10.17352/ijcem.000026 en Copyright © Rim Hanna et al.